Icosapent

Lowering Triglycerides

Icosapent is primarily used to treat adults with severe hypertriglyceridemia, a condition characterized by very high levels of triglycerides (fats) in the blood. It is intended to be used in combination with a low-fat and low-cholesterol diet to help manage these levels.

Reducing Cardiovascular Risk

This medication is also prescribed to reduce the risk of serious cardiovascular events in specific groups of adults. It may be used for individuals who have:

• Established cardiovascular (heart and blood vessel) disease, or
• Diabetes along with two or more additional risk factors for heart disease.

In these patients, icosapent is used to help lower the risk of:

• Heart attack
• Stroke
• The need for certain heart surgeries (coronary revascularization)
• Hospitalization for unstable angina (severe chest pain)

Icosapent is typically used as an add-on treatment for patients who are already taking the maximum tolerated dose of a statin (a common cholesterol-lowering medication) but still have elevated triglyceride levels.

Mechanism of Action

Icosapent is a highly purified version of eicosapentaenoic acid (EPA), which is an omega-3 fatty acid. It is classified as an antilipemic agent, a type of medication used to lower lipid (fat) levels in the blood.

The primary way icosapent works is by decreasing the liver's production of triglycerides. While the exact biological processes are not entirely understood, researchers believe the medication works through several pathways:

• Reducing fat production: It may inhibit certain enzymes in the liver that are responsible for creating triglycerides.
• Increasing fat clearance: It may help the body more effectively remove very-low-density lipoprotein (VLDL) particles, which carry triglycerides, from the bloodstream.
• Enhancing fat breakdown: It may increase the activity of enzymes that break down fats in the blood and liver.

By lowering triglyceride levels, icosapent helps manage conditions where these fats are excessively high, which is often done in conjunction with dietary changes.

Common Side Effects

Some people taking icosapent may experience mild side effects. These often include:

• Joint or muscle pain
• Swelling of the hands, legs, or feet
• Constipation
• Gout
• Pain in the mouth or throat

Serious Side Effects

While less common, some side effects can be serious. Seek medical attention immediately if you notice:

• Heart rhythm problems: Symptoms may include a fast or irregular heartbeat, dizziness, lightheadedness, fainting, or shortness of breath.
• Bleeding issues: This may include unusual bruising, nosebleeds, or bleeding that does not stop easily.
• Allergic reactions: Signs include a skin rash, hives, or swelling of the face, lips, or throat.
• Chest pain

The risk of heart rhythm issues like atrial fibrillation or atrial flutter may be higher in individuals with a history of these conditions. Additionally, icosapent may increase the risk of bleeding, particularly for those also taking blood-thinning medications such as aspirin, warfarin, or clopidogrel.

Atrial Fibrillation and Flutter

Icosapent ethyl is associated with an increased risk of atrial fibrillation or atrial flutter requiring hospitalization. This risk appears to be higher in individuals who have a prior history of these heart rhythm conditions.

Bleeding Risk

There is an increased risk of bleeding associated with the use of this medication. The risk may be higher for individuals who are also taking other medications that affect blood clotting, such as anticoagulants (blood thinners) or antiplatelet agents.

Fish and Shellfish Allergy

It is not known whether patients with allergies to fish or shellfish are at an increased risk of an allergic reaction to icosapent ethyl. The medication should be used with caution in individuals with a known hypersensitivity to fish or shellfish.

Hypersensitivity and Contraindications

Icosapent ethyl is contraindicated in patients with a known hypersensitivity to icosapent ethyl or any of its components. Serious allergic reactions, including anaphylaxis, have been reported in some cases.

Monitoring

Healthcare providers may perform periodic blood tests to monitor lipid levels. For individuals with hepatic impairment (liver disease), periodic monitoring of liver enzyme levels, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), may be recommended during treatment.

Pregnancy

There is limited information regarding the use of icosapent in pregnant women. Current data from clinical reports are insufficient to determine if the medication increases the risk of birth defects, miscarriage, or other adverse outcomes for the mother or the fetus. In animal studies, no developmental harm was observed even at doses significantly higher than those typically prescribed to humans.

Breastfeeding

It is not known whether icosapent passes into human breast milk or how it might affect a nursing infant or milk production. However, omega-3 fatty acids are known to be excreted in human milk. When deciding whether to use this medication while breastfeeding, healthcare providers typically consider the mother's clinical need for the drug alongside the potential benefits of breastfeeding for the child.

Consult Your Doctor

If you are pregnant, planning to become pregnant, or are currently breastfeeding, it is important to speak with your doctor. They can help evaluate the necessity of the medication compared to any potential risks to the baby.

Available Forms

Icosapent is provided as a liquid-filled gel capsule intended for oral administration. These capsules are typically swallowed whole and should not be crushed, chewed, or dissolved before ingestion.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) has approved icosapent for two primary uses in adults:

• Severe Hypertriglyceridemia: It is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe elevations (500 mg/dL or higher).
• Cardiovascular Risk Reduction: It is approved as an add-on therapy to maximally tolerated statin treatment to reduce the risk of heart attack, stroke, and certain heart procedures. This indication applies to adults with triglyceride levels of 150 mg/dL or higher who have either established cardiovascular disease or diabetes plus two or more additional risk factors for heart disease.

Regulatory Safety Information

There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with icosapent. However, the FDA and clinical studies have noted specific safety considerations:

• Atrial Fibrillation and Flutter: Clinical trials observed an increased risk of heart rhythm issues, such as atrial fibrillation or atrial flutter, requiring hospitalization. This risk may be higher in individuals with a history of these conditions.
• Bleeding Risk: Some data suggests an increased risk of bleeding, particularly in patients who are also taking other medications that affect blood clotting, such as aspirin or anticoagulants.

Factors Influencing Cost

Several factors determine the out-of-pocket expense for icosapent:

• Generic Availability: Icosapent ethyl is available as a generic medication and as the brand-name drug Vascepa. Generic versions typically cost less than brand-name products.
• Insurance and Medicare: Many insurance plans and Medicare Part D cover icosapent. The final cost depends on the specific plan's formulary, copayments, and whether the annual deductible has been met.
• Pharmacy Selection: Prices for prescription medications can differ between retail pharmacies. Comparing prices at different locations or using mail-order services may result in savings.

Financial Assistance Programs

For those who have difficulty affording the medication, options may include:

• Manufacturer Savings: Some manufacturers offer savings cards or coupons for eligible patients with commercial insurance to help lower copay costs.
• Patient Assistance: Programs may be available to provide the medication at a reduced cost or for free to individuals who meet specific financial criteria and lack adequate insurance coverage.